Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Belgium's UCB Is Almost Over Its Patent Cliff, But Guides Revenues And Profits To Decline In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

UCB Pharma's trio of new products is managing, for now, to compensate for the generic erosion to its best-selling anti-epileptic Keppra.

You may also be interested in...



Epilepsy NMEs: A View Of The Playing Field

The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.

Epilepsy NMEs: A View Of The Playing Field

The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.

UCB’s Neupro Returns To U.S. Market With New Formulation, Indications

FDA approves a new version of UCB’s skin patch for treatment of advanced Parkinson’s disease and restless leg syndrome. The new product, which contains different excipients to prevent crystallization, will be available in July.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel